** Shares in Galderma GALD.S rise 5.7% after the company posted Q1 results that beat expectations, driven by higher sales, especially in its Injectable Aesthetics division
** Sales in Injectable Aesthetics were up 9.9% y/y, which analysts at Jefferies and J.P. Morgan point to as 6% above consensus, driven primarily by Neuromodulators sales
** U.S. sales did not reach consensus expectations but this was offset by "pleasing double-digits" growth in international sales, Vontobel says
** The U.S. sales launch of atopic dermatitis and prurigo nodularis medication Nemluvio was stronger than expected, analysts say, with Jefferies seeing the trajectory as "promising when compared to Sanofi SASY.PA/Regeneron's REGN.O Dupixent and Eli Lilly's LLY.N Ebglyss"
** Up to the previous session's close, shares were down 19.9% YTD
(Reporting by Bernadette Hogg)
((bernadette.hogg@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。